• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Combination Antiviral Therapy for Influenza: Predictions from Modeling of Human Infections

tetano

Editor, Senior Moderator
J Infect Dis. 2012 Mar 23. [Epub ahead of print]
Combination Antiviral Therapy for Influenza: Predictions from Modeling of Human Infections.
Perelson AS, Rong L, Hayden FG.
Source

Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545.
Abstract

Emergence of resistance is a major concern in influenza antiviral treatment and prophylaxis. Combination antiviral therapy might overcome this problem. Here, we estimate that all possible single mutants and a sizeable fraction of double mutants are generated during an uncomplicated influenza infection. While many of them may sustain a fitness cost, some variants may confer drug resistance and be selected during therapy. We argue that a triple combination regimen would markedly reduce the risk of antiviral resistance emergence in seasonal and pandemic influenza viruses, especially in seriously ill or immunocompromised hosts.

PMID:
22448006
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/22448006
 
Back
Top Bottom